Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Thorax

• Publication date

  1993-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/thx.48.2.134PMID 8493626PMCID PMC464288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Subsensitivity of beta-adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol

  2004cited by this paper
• Chronic persistent cough: use of ipratropium bromide in undiagnosed cases following upper respiratory tract infection.

  1992cited by this paper
• Legal status of dead "patients".

  1992cited by this paper
• Chlamydia pneumoniae infection and asthma.

  1992cited by this paper
• Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group.

  1992cited by this paper
• A comparison of several tests for censored paired data.

  1992cited by this paper
• Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study.

  1991cited by this paper
• Cough variant asthma: a review of the clinical literature.

  1991cited by this paper
• Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained.

  1991cited by this paper
• Regular inhaled beta-agonist treatment in bronchial asthma.

  1990cited by this paper
• Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol.

  1990cited by this paper
• Is current treatment increasing asthma mortality and morbidity?

  1989cited by this paper
• Diagnosis of occupational asthma

  1989cited by this paper
• Increase in hospital admissions for childhood asthma: trends in referral, severity, and readmissions from 1970 to 1985 in a health region of the United Kingdom.

  1989cited by this paper
• International trends in asthma mortality: 1970 to 1985.

  1988cited by this paper
• Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline.

  1988cited by this paper
• Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma.

  1987cited by this paper
• Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not.

  1987cited by this paper
• SPSS-X advanced statistics guide

  1985cited by this paper
• Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

  1985cited by this paper
• Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects.

  1982cited by this paper
• Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects.

  1982cited by this paper
• Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration.

  1982cited by this paper
• Prediction formulae for normal pulmonary function values in New Zealand European subjects.

  1980cited by this paper
• Comparison of four weeks' treatment with fenoterol and terbutaline aerosols in adult asthmatics. A double-blind crossover study.

  1979cited by this paper
• Evaluation of oral fenoterol in chronic asthmatic patients.

  1978cited by this paper
• Bronchial reactivity to inhaled histamine: a method and clinical survey

  1977cited by this paper
• Asthma induced by adrenergic aerosols.

  1973cited by this paper
• Asthma induced by adrenergic aerosols.

  1970cited by this paper
• Iatrogenic asthma associated with adrenergic aerosols.

  1966cited by this paper

• The Wiser Strategy of Using Beta-Agonists in Asthma: Mechanisms and Rationales

  2024cites this paper
• Risk of pneumonia in asthmatic children using inhaled corticosteroids: a nested case-control study in a birth cohort

  2022cites this paper
• Effects of Asthma Medication Type on Asthma Exacerbation in a Real-World Setting

  2022cites this paper
• Over-the-Counter Availability of Rescue Inhalers for Asthma.

  2022cites this paper
• [Physical and Clinical Aspects of Inhalation Therapy for Asthma and COPD].

  2020cites this paper
• Comparison of Efficacy of Metered Dose Inhaler and Dry Powder Inhalation in Treatment of Persistent Asthma

  2018cites this paper
• Paradoxical Bronchoconstriction with Short-Acting Beta Agonist

  2018cites this paper
• As‐Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma

  2018cites this paper
• Long-Acting β2-Agonists in Asthma: Enantioselective Safety Studies are Needed

  2018influential citation
• Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma.

  2017cites this paper
• β2-Adrenoceptor Function in Asthma.

  2017cites this paper
• 42 – Asthma: Clinical Diagnosis and Management

  2016cites this paper
• Heat Shock-Related Protein 20 Peptide Decreases Human Airway Constriction Downstream of β2-Adrenergic Receptor.

  2016cites this paper
• Mast cells in asthma – state of the art

  2016cites this paper
• Bidirectional Counterregulation of Human Lung Mast Cell and Airway Smooth Muscle β2 Adrenoceptors

  2016cites this paper
• Mast cells in airway diseases and interstitial lung disease.

  2016cites this paper
• A Cross-sectional Study of the Relationship Between Socioeconomic Status and the Magnitude of Short-Acting -Agonist Use in Asthma

  2015cites this paper
• Managing severe asthma in adults: lessons from the ERS/ATS guidelines

  2015cites this paper
• Seguridad de los beta 2 agonistas (?2a) en asma bronquial

  2014cites this paper
• International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

  2013cites this paper
• Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.

  2013cites this paper
• Clinical Management of Asthma in the 1990s

  2012cites this paper
• Long-Acting β2-Agonists

  2012cites this paper
• Inhaled Combination Therapy with Glucocorticoids and Long‐Acting β2‐Agonists in Asthma and COPD, Current and Future Perspectives

  2012cites this paper
• Oral vs Inhaled Asthma Therapy

  2012cites this paper
• Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.

  2012cites this paper
• Can Reactive Airways Dysfunction Syndrome (RADS) Be Iatrogenic?

  2011cites this paper
• Beta-2 agonist discussions in asthma and a review of current data.

  2011cites this paper
• A novel small molecule target in human airway smooth muscle for potential treatment of obstructive lung diseases: a staged high-throughput biophysical screening

  2011cites this paper
• Salmeterol: An inhaled /β2-agonist with prolonged duration of action

  2011cites this paper
• Mast cells in lung inflammation.

  2011cites this paper
• Improving the management of asthma and chronic obstructive pulmonary disease

  2011cites this paper
• Safe use of long-acting β-agonists: what have we learnt?

  2011cites this paper
• Lessons Learned From the Asthma Clinical Research Network

  2011cites this paper
• Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of β-receptor affinity in murine models of asthma

  2011cites this paper
• Pharmacogenetics of β2-agonists.

  2011cites this paper
• Counterregulation of beta(2)-adrenoceptor function in human mast cells by stem cell factor.

  2010cites this paper
• Beta-Adrenergic Agonists

  2010cites this paper
• Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease.

  2010cites this paper
• Epac as a novel regulator of airway smooth muscle phenotype and function: potential implications in asthma and COPD

  2010cites this paper
• Intervention to Reduce Unnecessary Dispensing of Short-Acting β-Agonists in Patients with Asthma

  2010cites this paper
• Adverse effects of salmeterol in asthma: a neuronal perspective

  2009cites this paper
• Beta‐2 adrenergic receptor genetic polymorphisms and asthma

  2009cites this paper
• β 2 -Adrenoceptor Agonists

  2009cites this paper
• Kontinuierliche Pulsfrequenzmessung als Möglichkeit der Steuerung der Belastungsintensität in ambulanten Lungensportgruppen

  2009cites this paper
• Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials

  2009cites this paper
• Importance of inhaler devices in the management of airway disease.

  2008cites this paper
• The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.

  2008cites this paper
• Safety and efficacy of beta agonists.

  2008cites this paper
• Análise do efeito agudo do brometo de tiotrópio na função pulmonar de crianças e adolescentes com fibrose cística.

  2008cites this paper
• Pharmacogenetic tests in asthma therapy.

  2008cites this paper
• Pharmacogenetics of asthma.

  2008cites this paper
• Genetic influences on response to asthma pharmacotherapy

  2008cites this paper
• Predicting asthma control and exacerbations: chronic asthma as a complex dynamic model

  2007cites this paper
• Salmeterol and cytokines modulate inositol-phosphate signalling in Human airway smooth muscle cells via regulation at the receptor locus

  2007cites this paper
• Pharmacogenetics of the response to beta 2 agonist drugs: a systematic overview of the field.

  2007cites this paper
• Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness

  2006cites this paper
• Risk versus benefit considerations for the beta(2)-agonists.

  2006cites this paper
• Epidemiology of asthma

  2006cites this paper
• Clinical concerns with inhaled β2-agonists

  2006cites this paper
• beta2-Adrenoceptor agonist modulates endothelin-1 receptors in human isolated bronchi.

  2006cites this paper
• Risk versus Benefit Considerations for the β2‐Agonists

  2006cites this paper
• Fenoterol: Pharmacology and Clinical Use

  2006cites this paper
• Childhood asthma: breakthroughs and challenges.

  2006cites this paper
• Concluding remarks

  2006cites this paper
• Advances in pediatric asthma and atopic dermatitis

  2005cites this paper
• Modulation of GM-CSF release by enantiomers of beta-agonists in human airway smooth muscle.

  2005cites this paper
• Risk of severe asthma episodes predicted from fluctuation analysis of airway function

  2005cites this paper
• As-needed inhaled beta2-adrenoceptor agonists in moderate-to-severe asthma: current recommendations.

  2005cites this paper
• Genetics and the variability of treatment response in asthma.

  2005cites this paper
• As-Needed Inhaled β2-Adrenoceptor Agonists in Moderate-to-Severe Asthma

  2005cites this paper
• Formoterol used as needed in patients with intermittent or mild persistent asthma.

  2005cites this paper
• Increase in daytime symptoms is a sensitive and specific criterion for predicting corticosteroid‐treated exacerbations in a clinical asthma trial

  2005cites this paper
• Past, present and future--beta2-adrenoceptor agonists in asthma management.

  2005cites this paper
• Monitoring the Impact of Asthma Drug Therapy: Database Studies

  2005cites this paper
• Nociceptin inhibits vanilloid TRPV-1-mediated neurosensitization induced by fenoterol in human isolated bronchi

  2004cites this paper
• Histamine H1 receptor down-regulation mediated by M3 muscarinic acetylcholine receptor subtype.

  2004cites this paper
• Are β2-adrenoceptor polymorphisms important in asthma—an unravelling story

  2004cites this paper
• Beta(2)-adrenergic receptor-mediated histamine H(1) receptor down-regulation: another possible advantage of beta(2) agonists in asthmatic therapy.

  2004cites this paper
• Adverse effects of short‐acting beta‐agonists: potential impact when anti‐inflammatory therapy is inadequate: Comment

  2004cites this paper
• Reconcilable differences: a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma.

  2004cites this paper
• Is There Any Advantage to Using Levalbuterol in the Treatment of Asthma?

  2004cites this paper
• Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.

  2004cites this paper
• Adverse effects of short‐acting beta‐agonists: Potential impact when anti‐inflammatory therapy is inadequate

  2004cites this paper
• An Endpoint for Worsening Asthma: Development of a Sensitive Measure and its Properties

  2004cites this paper
• Therapy for Virus-Induced Asthma Exacerbations Current Status and Future Prospects

  2003cites this paper
• Lung function, adherence and denial in asthma patients who exhibit a repressive coping style

  2003cites this paper
• Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment.

  2003cites this paper
• Cardioselective (cid:1) -Blockers in Patients with Reactive Airway Disease: A Meta-Analysis

  2002cites this paper
• Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves.

  2002cites this paper
• Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.

  2002cites this paper
• Cardioselective -Blockers in Patients with Reactive Airway Disease

  2002cites this paper
• Airways reactivity in patients with CF

  2002cites this paper
• Interactions of glucocorticoids and β 2-agonists

  2002cites this paper
• Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.

  2002cites this paper
• Beta2-Agonists: Friend or Foe?

  2002cites this paper
• Adverse effects of beta-agonists.

  2002cites this paper
• Cardioselective beta-blockers for reversible airway disease.

  2002cites this paper
• Adverse effects of -agonists

  2002cites this paper
• L'enfant siffleur de zéro à trois ans, approche thérapeutiqueThe wheezy child from birth to three years, a therapeutic approach.

  2002cites this paper